4d Pharma PLC Oncology candidate update (3629I)
21 March 2018 - 6:00PM
UK Regulatory
TIDMDDDD
RNS Number : 3629I
4d Pharma PLC
21 March 2018
4D pharma plc
(the "Company" or "4D")
Oncology candidate update
4D pharma plc (AIM: DDDD), a pharmaceutical company focusing on
the development of live biotherapeutics, provides the following
update in relation to the development of its lead oncology
candidate, MRx0518.
MRx0518 is a single strain bacterial Live Biotherapeutic Product
(LBP), isolated and purified from a healthy human faecal sample,
that has been shown to have immune-stimulatory characteristics and
activity in a number of pre-clinical cancer models. Following a
successful development programme at the Company's own GMP
production plant, plans are at an advanced stage to open clinical
studies in the UK and the US in the near future.
Data will be presented today at the Microbiome R&D and
Business Collaboration Forum, Rotterdam by 4D's Chief Executive
Officer, Duncan Peyton, identifying key aspects of the mode of
action of MRx0518. Research carried out by 4D has identified a
specific component of the bacteria, flaA, that plays a key role in
the activity of MRx0518 by stimulating pathways that are known to
be associated with the body's response to cancer. Interaction of
flaA with the human protein Toll Like Receptor 5 (TLR5) has been
linked to the activity of MRx0518 in pre-clinical cancer models and
this will be investigated further in upcoming clinical trials.
Duncan Peyton, 4D's Chief Executive Officer, commented: "This is
a key step in the development of a true microbiome derived
pharmaceutical product for the treatment of cancer. Understanding
the mode of action of MRx0518, through the identification of a
specific gene product and its interaction with a high profile human
oncology target, gives greater insight into its potential
applications and benefits to cancer patients. We look forward to
reporting further progress as we move into the clinical phases of
development of MRx0518."
For further information please contact:
4D + 44 (0)113 895 0130
Duncan Peyton, Chief Executive Officer
Zeus Capital Limited - Nomad and Joint Broker
Dan Bate / Jordan Warburton +44 (0) 161 831 1512
Hugh Kingsmill Moore +44 (0) 203 829 5000
Bryan Garnier & Co. Limited - Joint Broker +44 (0)20 7332 2500
Dominic Wilson
Phil Walker
About 4D
Founded in February 2014, 4D is a world leader in the
development of live biotherapeutics, a novel and emerging class of
drugs, defined by the FDA as biological products that contain a
live organism, such as a bacteria, that is applicable to the
prevention, treatment or cure of a disease. 4D has developed a
proprietary platform that rationally identifies novel bacteria that
have a precise and evolved therapeutic effect. All of 4D's live
biotherapeutic products are orally delivered single strains of
bacteria that are naturally found in the healthy human gut. 4D has
completed a phase I study in Irritable Bowel Syndrome and has
recently completed dosing in a phase I study in Paediatric Crohn's
Disease. It currently has a pipeline of 13 pre-clinical programmes,
covering disease areas such as cancer, poorly controlled asthma,
autoimmune and CNS disease, and plans to commence four additional
clinical studies in 2018.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RESPGUUCWUPRGBU
(END) Dow Jones Newswires
March 21, 2018 03:00 ET (07:00 GMT)
4d Pharma (LSE:DDDD)
Historical Stock Chart
From Apr 2024 to May 2024
4d Pharma (LSE:DDDD)
Historical Stock Chart
From May 2023 to May 2024